MAIA Biotechnology, Inc. (MAIA) is a publicly traded Healthcare sector company. As of July 8, 2026, MAIA trades at $1.47 with a market cap of $88.77M and a P/E ratio of -2.05. MAIA moved -0.68% today. Year to date, MAIA is +10.53%; over the trailing twelve months it is -19.67%. Its 52-week range spans $0.87 to $3.19. Analyst consensus is buy with an average price target of $14.00. Rallies surfaces MAIA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
MAIA Biotechnology’s THIO-101 Part C Shows 90.5% Disease Control Rate: MAIA reports a 90.5% disease control rate (19 of 21 patients) with ateganosine plus cemiplimab in its Phase 2 THIO-101 Part C third-line NSCLC trial expansion. All patients had prior docetaxel, immunotherapy and chemotherapy resistance, compared with typical 25–35% control rates for standard third-line chemotherapy.
| Metric | Value |
|---|---|
| Price | $1.47 |
| Market Cap | $88.77M |
| P/E Ratio | -2.05 |
| EPS | $-0.70 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.19 |
| 52-Week Low | $0.87 |
| Volume | 987.24K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-22.40M |
| Gross Margin | 0.00% |
1 analysts cover MAIA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.00.